teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 52 Projects Releases Packages Wiki Activity Actions 1

extract: 2025-04-01-jmir-glp1-digital-engagement-outcomes-retrospective

Browse source 
Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>
This commit is contained in:
Teleo Agents 2026-03-24 04:30:23 +00:00
parent 6a0aeb9a74
commit 73d141b8f7
2 changed files with 20 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

6
domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
View file

@ -114,6 +114,12 @@ Aon data shows benefits scale dramatically with adherence: for diabetes patients
Novo Nordisk's response to India's generic launch reveals market expansion strategy: only 200,000 of 250 million obese Indians are currently on GLP-1s. The company is competing on 'market expansion over price war,' suggesting the primary barrier is access/awareness, not price sensitivity. This implies persistence challenges may be access-driven in international markets rather than purely adherence-driven. Novo Nordisk's response to India's generic launch reveals market expansion strategy: only 200,000 of 250 million obese Indians are currently on GLP-1s. The company is competing on 'market expansion over price war,' suggesting the primary barrier is access/awareness, not price sensitivity. This implies persistence challenges may be access-driven in international markets rather than purely adherence-driven.
### Additional Evidence (extend)
*Source: [[2025-04-01-jmir-glp1-digital-engagement-outcomes-retrospective]] | Added: 2026-03-24*
US real-world data from JMIR 2025 shows digital engagement produces 11.53% weight loss vs. 8% for non-engaged participants at month 5 (3.5pp advantage). Study covers both semaglutide and tirzepatide, demonstrating the behavioral support effect generalizes across GLP-1/GIP receptor agonists. When supply and coverage issues are addressed, persistence improves to 63%, suggesting the adherence gap is partially addressable through digital platform integration (live coaching, monitoring, education).
Relevant Notes: Relevant Notes:
- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] - [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]

15
inbox/queue/2025-04-01-jmir-glp1-digital-engagement-outcomes-retrospective.md
View file

@ -7,9 +7,13 @@ date: 2025-04-01
domain: health domain: health
secondary_domains: [] secondary_domains: []
format: research-paper format: research-paper
status: unprocessed status: enrichment
priority: medium priority: medium
tags: [glp1, semaglutide, digital-health, behavioral-support, adherence, weight-loss, atoms-to-bits, belief-4, real-world-data] tags: [glp1, semaglutide, digital-health, behavioral-support, adherence, weight-loss, atoms-to-bits, belief-4, real-world-data]
processed_by: vida
processed_date: 2026-03-24
enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"]
extraction_model: "anthropic/claude-sonnet-4.5"
--- ---
## Content ## Content
@ -59,3 +63,12 @@ PMC archive: PMC11997532.
PRIMARY CONNECTION: Belief 4 atoms-to-bits + Session 4/5 GLP-1 adherence thread PRIMARY CONNECTION: Belief 4 atoms-to-bits + Session 4/5 GLP-1 adherence thread
WHY ARCHIVED: US real-world confirmation of Danish study finding; adds data point for oral semaglutide FDA approval as a potential adherence game-changer WHY ARCHIVED: US real-world confirmation of Danish study finding; adds data point for oral semaglutide FDA approval as a potential adherence game-changer
EXTRACTION HINT: Update existing GLP-1 adherence claim with US real-world data; create new claim for oral semaglutide adherence pathway if not already in KB EXTRACTION HINT: Update existing GLP-1 adherence claim with US real-world data; create new claim for oral semaglutide adherence pathway if not already in KB
## Key Facts
- JMIR 2025 study (PMC11997532) shows engaged GLP-1 users achieve 11.53% mean weight loss vs. 8% for non-engaged at month 5
- Study covers both semaglutide and tirzepatide, demonstrating cross-molecule effect
- GLP-1 persistence improves from ~50% to 63% when supply and coverage issues are addressed
- Danish study previously showed online weight-loss program + semaglutide at half typical dose → 16.7% weight loss over 64 weeks
- Oral semaglutide received FDA approval for weight management in 2026
- Digital platform components: live group video coaching, text-based in-app support, dynamic educational content, real-time weight monitoring, medication adherence tracking